-
Mashup Score: 7
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-posit ive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug Administration (FDA)-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. The approval was granted by the FDA after securing Priority Review
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-posit ive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug Administration (FDA)-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. The approval was granted by the FDA after securing Priority Review
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Enhertu is approved for low or ultralow HER2 after one line of endocrine therapy. I understand the data. Is it truly a bad idea to give T-DXd after Xeloda for low-volume or slow-growing diseases? Can you not give T-DXd after Xeloda? https://t.co/wGsquPFTI3
-
-
Mashup Score: 7
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-posit ive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug Administration (FDA)-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. The approval was granted by the FDA after securing Priority Review
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Enhertu is approved for low or ultralow HER2 after one line of endocrine therapy. I understand the data. Is it truly a bad idea to give T-DXd after Xeloda for low-volume or slow-growing diseases? Can you not give T-DXd after Xeloda? https://t.co/wGsquPFTI3
-
-
Mashup Score: 2Advancing Gene Editing with ePsCas9 Technology - 2 month(s) ago
Discover how ePsCas9 technology is revolutionising gene editing with enhanced precision and potential to treat rare genetic disorders.
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet-
New research in @NatureComms shows how our ePsCas9 gene editing system offers greater precision. This specificity represents an important advancement in #GenomicMedicine with potential for many rare diseases. Learn more: https://t.co/GifFe3Jmsl https://t.co/BoIrZkYVYS
-
-
Mashup Score: 66
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 1Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer - 3 month(s) ago
AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC). The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious cond itions or enhancing patient compliance. 1 The
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/AIO6EM9Dys
-
-
Mashup Score: 65
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 65
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 65
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
-
Mashup Score: 65
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial 👏👏 @GuardConsortium @OncoAlert https://t.co/cHKC2ddkmy
-
Enhertu is approved for low or ultralow HER2 after one line of endocrine therapy. I understand the data. Is it truly a bad idea to give T-DXd after Xeloda for low-volume or slow-growing diseases? Can you not give T-DXd after Xeloda? https://t.co/wGsquPFTI3